Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab Combination in Relapsed/Refractory Multiple Myeloma
NCT03952091Phase 3Completed
- Sponsor
- TJ Biopharma
- Start
- Mar 2019
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of felzartamab in multiple myeloma (MM), sponsored by TJ Biopharma. Started Mar 2019; status: completed.
02
Drugs
felzartamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03952091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952091.